Sanofi research snapshot
SNY AI stock analysis currently views Sanofi as a profitable global biopharma company that just raised 2026 guidance on strong Dupixent and pharma-launch momentum, while a new chief executive prioritizes the pipeline. At the August 2, 2026 data cutoff, SNY last closed at $43.08 on July 31 and the reported market capitalization was $102.63 billion. The setup combines low forward valuation and a 4.1% dividend yield with concentration, pipeline, pricing, and leadership-transition risks. This page is informational research, not investment advice.
Current price
$43.08
Market cap
$102.63 billion
AI score
67 / 100
Rating
Strong near-term growth with rising Dupixent concentration and pipeline prioritization risk
Trend status
Below the 50-day and 200-day moving averages with neutral momentum after the post-earnings decline
Data cutoff (updated monthly)
August 4, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Sanofi converts research, clinical development, regulatory approvals, biologics manufacturing, and commercial access into recurring sales of medicines and vaccines, with Q2 net sales up 17.8% at constant exchange rates. | High |
| Moat | Patents, clinical evidence, physician trust, global manufacturing, regulatory know-how, and distribution support the franchise, but product exclusivity is finite and payer power matters. | Medium-high |
| Management | CEO Belen Garijo is running an accelerated transformation roadmap, prioritizing the pipeline, and completed a EUR 1 billion buyback. Discontinued programs add execution and signaling risk to monitor. | Medium |
| Financial trend | H1 2026 net sales reached EUR 22.106 billion, up 15.7% at constant exchange rates, with business EPS of EUR 3.97, up 22.7% at CER. Q2 business EPS grew 33.3% at CER to EUR 2.09. | High |
| Valuation | The August 2 snapshot shows a forward PE of 8.4x and a P/FCF of 8.9x. The 22.7x trailing IFRS PE is elevated because Q2 2026 IFRS EPS fell to EUR 0.29 on one-time charges, while business EPS grew strongly. | Medium-high |
| Technical trend | SNY was below both the 50-day average of $43.51 and the 200-day average of $46.51, with RSI near 46.8. The longer-term chart needs confirmation after the post-earnings drop. | Medium |
| Risk level | Risk is medium-high because Dupixent represented 36.0% of FY2025 net sales and an even larger share of Q2 2026 sales, and pipeline prioritization plus pharmaceutical pricing pressure add uncertainty. | High |
| AI confidence | Reported facts and current market inputs are well documented, but AI cannot turn clinical outcomes, pipeline decisions, or investor sentiment into a dependable price prediction. | High data confidence |
| Investment certainty | Medium-low certainty. A potential margin of safety exists only if Dupixent, pharma launches, vaccines, and a rebuilt pipeline offset future concentration and pricing pressure. | Medium-low |
SNY AI stock forecast
The SNY AI stock forecast uses audited scenario math around the $43.08 July 31 close and roughly $4.80 of normalized business EPS per ADS. A three-year framework produced a bearish area near $37, a base area near $57, and a bullish area near $75. These are conditional scenarios before dividends, not price promises.
$70 to $78 over three years
More likely if Dupixent keeps compounding toward the ~EUR 25 billion 2030 ambition, pharma launches scale, vaccines recover, pipeline reprioritization delivers approvals, 2026 guidance is met, and investors sustain an earnings multiple near 12x.
$54 to $60 over three years
More likely if business EPS compounds near 6% annually, buybacks continue, pricing and currency remain manageable, and the market values SNY near a 10x earnings multiple on normalized business EPS.
$34 to $40 over three years
More likely if Dupixent growth slows, pipeline prioritization cuts more programs, trial or launch execution disappoints, price pressure intensifies, or the market compresses the multiple toward 8x.
SNY AI technical analysis
SNY AI technical analysis is cautious at the August 2, 2026 cutoff. StockAnalysis recorded a July 31 close of $43.08, a 50-day moving average of $43.51, a 200-day moving average of $46.51, RSI of 46.84, and a 20-day average volume of 3.46 million shares. These are chart snapshots, not forecasts.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $43.08 | StockAnalysis recorded the July 31, 2026 closing price, down from the prior session as investors weighed Q2 results and pipeline updates. |
| Near support | $42.50 to $43.00 | This is the recent intraday zone around the day range low of $42.48. Holding it would keep the short-term stabilization case intact. |
| Major support | $40.89 | The reported 52-week low is $40.89. A sustained break below this zone would weaken the range-trading thesis. |
| Near resistance | $43.51 | The 50-day moving average sits at $43.51. Reclaiming it would improve the short-term trend read. |
| Major resistance | $46.51 | The 200-day moving average is $46.51. Closing above it would materially improve the longer-term trend picture. |
| 50-day moving average | $43.51 | Price was slightly below this short-term reference on July 31, and one close does not establish a trend. |
| 200-day moving average | $46.51 | Price remained well below this longer-term reference, leaving overhead resistance in place. |
| Momentum | RSI 46.84 | RSI was neutral, neither confirming an oversold reversal nor strong momentum after the earnings drop. |
| Volume | 20-day average 3.46 million shares | Compare any move through support or resistance with this recent activity level, especially around results and clinical news. |
| Volatility | $40.89 to $52.68 52-week range, beta 0.28 | A low beta does not prevent event-driven gaps in an individual biopharma ADR. |
| Invalidation | Sustained close below $40.89 | A break below the reported 52-week low would invalidate this range-based technical framework and require a fresh chart review. |
SNY AI trading strategy
The SNY AI trading strategy is a rules-based research framework for a large biopharma ADR. It is not personal advice. Refresh the live chart, company filings, clinical disclosures, and position-sizing rules before acting.
Wait for SNY to hold the $42.50 to $43.00 zone and then reclaim the $43.51 50-day average, followed by the $46.51 200-day average, on stronger volume. That sequence would provide better trend confirmation than buying a single up day.
A sustained close below $40.89 or a material deterioration in sales, guidance, or clinical evidence should invalidate the setup.
If SNY revisits the $40.89 to $43.00 support band, compare the forward valuation with the next results, Dupixent sales, pharma-launch momentum, vaccines, and management guidance before treating a lower price as an opportunity.
Do not average down without a predefined loss limit. Product, regulatory, and trial events can gap an ADR through ordinary stop levels.
Track Dupixent and pharma-launch sales; business EPS guidance; pipeline prioritization and readouts; IFRS charges; free cash flow; buybacks; pricing and reimbursement; vaccines; and the transformation roadmap under the new CEO.
Reduce confidence if growth relies more heavily on one product, acquisitions, or buybacks while new-product revenue, cash generation, and pipeline productivity weaken.
Investment research summary
Sanofi turns research, clinical evidence, regulatory approvals, manufacturing, and commercial access into recurring sales of specialty medicines and vaccines. Patients, physicians, health systems, and payers pay when a therapy has differentiated clinical value and reimbursement support.
The moat combines patents, biologics and vaccine manufacturing, clinical evidence, regulatory capability, trusted brands, physician relationships, and global distribution. It is strongest in differentiated products and weaker as exclusivity expires or similar therapies reach the market.
The thesis can fail if Dupixent concentration rises further, pipeline prioritization cuts too much future value, competition or reimbursement reduces realized prices, trials disappoint, launches do not scale, vaccine demand softens, acquisitions fail to earn their cost of capital, or currency and debt weigh on owner returns.
CEO Belen Garijo is prioritizing the pipeline and running a transformation roadmap after raising 2026 guidance. The leadership test is whether this reprioritization can diversify earnings, sustain research productivity, and preserve financial flexibility rather than simply extend a product cycle.
Immunology, specialty care, rare disease, oncology, and adult vaccines address durable medical demand. The industry also faces payers with purchasing power, policy intervention, trial risk, manufacturing constraints, and recurring patent cycles.
At the July 31 close, the verified snapshot showed a forward PE of 8.4x and a P/FCF of 8.9x on normalized earnings. That valuation may offer room for error only if growth products and a rebuilt pipeline replace mature-product pressure without eroding returns on capital.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| SNY price and market capitalization | $43.08 July 31 close and $102.63 billion reported market cap | StockAnalysis SNY statistics | August 2, 2026 |
| ADR mechanics and market-cap verification | One ordinary Sanofi share equals two ADSs. $43.08 x 2.38 billion ADS equivalents equals $102.62 billion, a 0.01% difference from the reported market cap. | Sanofi ADR program and financial_rigor.py market-cap verification | August 2, 2026 |
| Q2 2026 and H1 2026 results | Q2 net sales EUR 11.597 billion, up 17.8% at CER, and business EPS of EUR 2.09, up 33.3% at CER. H1 net sales EUR 22.106 billion and business EPS EUR 3.97, up 22.7% at CER. | Sanofi Q2 2026 results press release | August 2, 2026 |
| Q2 2026 IFRS results | Q2 IFRS net income fell to EUR 343 million and IFRS EPS to EUR 0.29, down about 91%, reflecting one-time charges and pipeline prioritization costs. | Sanofi Q2 2026 results press release | August 2, 2026 |
| 2026 guidance and 2030 ambitions | 2026 sales now expected to grow around 10% at CER with business EPS slightly faster than sales, after the July 30 upgrade. Dupixent targeted near EUR 25 billion and pharma launches near EUR 10 billion by 2030 at CER. | Sanofi Q2 2026 results press release | August 2, 2026 |
| Dupixent concentration and momentum | Dupixent rose 37.6% to EUR 5.2 billion in Q2 2026, above EUR 5 billion for a quarter for the first time. It represented 36.0% of FY2025 net sales. | Sanofi Q2 2026 results and Form 20-F 2025 | August 2, 2026 |
| Pipeline prioritization | Sanofi will not progress amlitelimab to global regulatory submission for atopic dermatitis, and discontinued the itepekimab and balinatunfib clinical programs as part of the pipeline review. | Sanofi Q2 2026 results press release | August 2, 2026 |
| Technical and valuation snapshot | 50-day average $43.51, 200-day average $46.51, RSI 46.84, forward PE 8.43x, trailing PE 22.70x, P/FCF 8.86x, and dividend yield 4.10%. | StockAnalysis SNY statistics | August 2, 2026 |
This SNY page is an informational research tool, not investment advice or a recommendation to buy or sell securities. Forecasts are conditional scenarios based on available data and assumptions. They can be wrong, and market, clinical, regulatory, pricing, currency, and company-specific events can cause losses.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
